Glioblastoma, an aggressive primary brain tumor type, is considered an immunologically "cold" tumor with sparse infiltration by adaptive immune cells. Immunosuppressive tumor-associated myeloid cells are drivers of tumor progression. Targeting and reprogramming intratumoral myeloid cells induces tumor regression in experimental glioma without requiring adaptive immunity. read more …

The network brings together six top sites of clinical brain research and offers career prospects for excellent young researchers. read more ...

Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells. read more …

The chronic exhaustion syndrome "fatigue" occurs as a consequence of surviving a COVID-19 infection. By studying a total of 100 patients, researchers from three scientific institutions in Baden-Württemberg want to gain new insights into fatigue to identify new targets for the therapy of fatigue associated with long-COVID. read more …

Prof. Simon Wiegert has been appointed by the University of Heidelberg to the W3 professorship in neurophysiology and heads the Department of Neurophysiology, since October 2022. He and his team will study the relationship between neuromodulation, neuronal plasticity and long-lasting changes in neuronal networks, with a particular focus on the plasticity of synaptic connections. read more …

Prof. Rolf-Detlef Treede, head of the Department of Neurophysiology has been awarded the John J. Bonica Prize at the World Congress of the International Association for the Study of Pain (IASP). The professional society awards the prize every two years to a person who has made major contribution to pain research or therapy. read more …